Trial Dims Prospects for Rivaroxaban’s Cardiovascular Protection in Advanced CKD
TRACK was the first dedicated placebo-controlled trial to test an anticoagulant for protection from hard cardiovascular outcomes in patients with advanced CKD at high cardiovascular risk. In this population, historically…
